Orphan Drugs
-
On the Horizon — Orphan Drugs and IRA
Read more: On the Horizon — Orphan Drugs and IRANot everything can be important, or nothing is. It’s the time of year when white boards and Post-It easels come out and prioritization for 2025 gets reviewed. From a consultant perspective, I love these exercises. It allows for a look at what needs direct action, coalition or monitoring. And the $ has to go to…
-
Orphan drug: Expand the label and you lose
Read more: Orphan drug: Expand the label and you loseFrom a patient perspective, the Inflation Reduction Act (IRA) definitely has some upside. Starting in 2024, the out-of-pocket cap in the Medicare prescription drug benefit starting is fantastic for beneficiaries taking more expensive products. Although this is a minority of patients, it still gives piece of mind to many knowing that if they find themselves…
Latest news
- Caught my eye — 11/22/24
- Caught my eye — 11/15/24
- Caught my eye — 11/8/24
- Caught my eye — 11/1/24
- Caught my eye — 10/25/24
Categories
- 340B (26)
- Affordable Care Act (3)
- Alzheimer's (4)
- Biosimilars (18)
- Caught my eye (47)
- Chevron Deference (2)
- CMMI (8)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (24)
- Drug shortages (7)
- DTC (2)
- Employers (7)
- Generics (3)
- Health Equity (3)
- Healthcare Costs (22)
- ICER (5)
- Importation (2)
- Inflation Reduction Act (40)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (3)
- Medicare Advantage (12)
- Medicare Negotiation (41)
- Medicare Part D (36)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (6)
- Obesity (18)
- On the Horizon (1)
- Orphan Drugs (2)
- Pharmacy Benefit Managers (23)
- Reference Pricing (3)
- State-based Reform (13)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (2)
- Value (7)